Located in Boston and the surrounding communities, Dana-Farber Cancer Institute brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
The Meyerson lab was the first to identify the association of Fusobacterium nucleatum with a subset of human colorectal cancers (Kostic et al., Genome Research, 2012, 22(2): 292–298). This work, published in parallel with Rob Holt's group that made the same discovery independently (Castellarin et al., Genome Research, 2012, 22(2): 299–306), led to further investigations describing the potential of F. nucleatum to accelerate intestinal tumorigenesis in mouse models (Kostic et al., Cell Host Microbe, 2013, 14(2): 207–215) and, most recently, to the discovery that Fusobacterium and its associated microbiota persist in colorectal cancers through the metastatic process and that antibiotic treatment of mice bearing Fusobacterium-containing human tumor xenografts diminishes tumor growth (Bullman et al., Science, 2017, 358(6369): 1443-1448).
Note: We request that candidates please apply only through the Dana-Farber careers website and not contact the Principal Investigator directly. Please include the names of 2-3 references in your application.